AJMC August 30, 2024
In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.
In part 1 of our interview with Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, hematologist-oncologist at University Hospitals Seidman Cancer Center, and assistant professor of medicine at Case Western Reserve University School of Medicine in Cleveland, Ohio, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma and what are the primary and secondary outcomes of the trial investigating this potential therapeutic approach. Here he continues the discussion by telling us of the benefits and challenges this treatment poses and how...
Today's Sponsors
Today's Sponsor